Treatment Indications: correction of deep wrinkles and severe folds (nasolabial folds, marionette lines, deep glabellar and forehead creases, perioral wrinkles);, volumization of cheeks, cheekbones, chin, jawline, and temporal region;, facial contouring and oval redefinition;, non‑surgical rhinoplasty and nasal deformity correction;, lip augmentation and contouring; hand rejuvenation;, restoration of facial volume loss and asymmetry correction
Release form: 1 × 1.0 mL pre‑filled sterile glass syringe
Indications: deep dermal, subdermal, and supraperiosteal injection for correction of deep wrinkles, severe folds, major volume restoration, and structural contouring;, densest hybrid gel in the ME:DAM line combining 85% stabilized HA and 15% free HA, utilizing L.T.S.R. (Low Temperature Stabilization Reaction) technology for maximum viscosity, high cohesivity, and stable shape retention;, two‑stage purification process reducing residual BDDE below 2 µg/mL; providing pronounced lifting effect, even tissue integration without lump formation, and minimal migration (effect duration ~9–12 months)